Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Hernández-Garcia MT, Novelli S, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. Bone Marrow Transplant. 2018 Jun;53(6):780-783. doi: 10.1038/s41409-018-0096-6. Epub 2018 Jan 23. PubMed PMID: 29362504.
AÑO: 2018; IF: 4.674
29362504
Martínez-Losada C, Serrano-López J, Serrano-López J, Noguera NI, Garza E, Piredda L, Lavorgna S, Consalvo MAI, Ottone T, Alfonso V, Peinado JR, Garcia-Ortiz MV, Morales-Ruiz T, Jérez A, Hurtado AM, Montesinos P, Cervera J, Such E, Ibañez M, Sempere A, Sanz MÁ, Lo-Coco F, Sánchez-García J. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. Haematologica. 2018 Sep;103(9):e400-e403. doi: 10.3324/haematol.2018.188433. Epub 2018 Apr 5. PubMed PMID: 29622659; PubMed Central PMCID: PMC6119134.
AÑO: 2018; IF: 7.57
29622659
Serna MJ, Rivera-Caravaca JM, Gonzalez-Conejero R, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, Roldán V, Marín F. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. Eur J Clin Invest. 2018 Jun;48(6):e12929. doi: 10.1111/eci.12929. Epub 2018 Apr 17. PubMed PMID: 29577257.
AÑO: 2018; IF: 5.722
29577257
Zeng W, Hu B, Tang L, You YY, Toderici M, Eugenia de la Morena-Barrio M, Corral J, Hu Y. Correction: Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency. Oncotarget. 2018 Feb 16;9(13):11428. doi: 10.18632/oncotarget.24519. eCollection 2018 Feb 16. PubMed PMID: 29542734; PubMed Central PMCID: PMC5834269.
AÑO: 2018
29542734
Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3. PubMed PMID: 30497432; PubMed Central PMCID: PMC6267080.
AÑO: 2018; IF: 2.933
30497432
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL